VivoSeq
Other

Keratoconjunctivitis Sicca

11

Pipeline Programs↗

0

Active Trials↗

10

Companies Involved↗

Keratoconjunctivitis sicca is an emerging landscape with 11 programs across 10 companies. The most active players are Can-Fite BioPharma, Rigel Pharmaceuticals, Aurinia Pharmaceuticals. 1 therapy is approved with 3 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

37/100

Pipeline Velocity

0/100

Mech. Concentration

20/100

Completion Rate

91/100

Attrition Rate

9/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

C

Can-Fite BioPharma

1 program

Phase 2R

Rigel Pharmaceuticals

1 program

Phase 2Aurinia Pharmaceuticals logo

Aurinia Pharmaceuticals

2 programs

Phase 2Sun Pharmaceutical Industries Limited logo

Sun Pharmaceutical Industries Limited

1 program

Phase 3Novartis logo

Novartis

1 program

Phase 3Sanofi logo

Sanofi

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

11

clinical trials

Completed10 · 91%
Withdrawn1 · 9%

Clinical Trials

Trial Activity

11 trials

Phase 2/3 Dose-Ranging Study of the Safety and Efficacy of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Completed·Sun Pharmaceutical Industries Limited logoSun Pharmaceutical Industries Limited·Phase 2/3·NCT02254265·455 enrolled
Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Completed·Sun Pharmaceutical Industries Limited logoSun Pharmaceutical Industries Limited·Phase 3·NCT02688556·745 enrolled
Efficacy and Safety of Fluorometholone (FML) in Dry Eye Disease (Keratoconjunctivitis Sicca)
Completed·IInstituto Universitario de Oftalmobiología Aplicada (Institute of Applied Ophthalmobiology) - IOBA·Phase 3·NCT02051023·41 enrolled
An Open-Label Extension of a Phase 3 Study of OTX-101 in the Treatment of Keratoconjunctivitis Sicca
Completed·Sun Pharmaceutical Industries Limited logoSun Pharmaceutical Industries Limited·Phase 3·NCT02845674·258 enrolled
A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)
Completed·LLux Biosciences, Inc.·Phase 1·NCT00851734·35 enrolled
Safety and Efficacy of Pimecrolimus Ophthalmic Suspension in Patients With Moderate to Severe Keratoconjunctivitis Sicca
Completed·Novartis logoNovartis·Phase 2·NCT00128245·440 enrolled
Lotemax® Gel 0.5% and Restasis 0.05% in Participants With Mild or Moderate Keratoconjunctivitis Sicca (Dry Eye Disease)
Completed·BBausch & Lomb Incorporated·Phase 2·NCT01817582·102 enrolled
Safety and Efficacy Study of CF101 to Treat Keratoconjunctivitis Sicca
Completed·CCan-Fite BioPharma·Phase 2·NCT00349466·80 enrolled
To Assess the Safety and Efficacy of R932348 Ophthalmic Solutions in Patients With Keratoconjunctivitis Sicca
Completed·RRigel Pharmaceuticals·Phase 2·NCT01900249·204 enrolled
Rebamipide Ophthalmic Suspension in the Treatment of Dry Eye: A Multicenter, Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, 26 Week Study
Completed·Otsuka logoOtsuka·Phase 3·NCT00201955·762 enrolled
Repository Corticotropin Injection in Keratoconjunctivitis Sicca
Withdrawn·UUniversity of Alabama at Birmingham·Phase 4·NCT03398018

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)